Status:
UNKNOWN
Survey and Reduction of Mortality in Peridialysis Uremic Patients Via Intervention of Risk Factors
Lead Sponsor:
Shanghai Changzheng Hospital
Conditions:
End Stage Renal Disease on Dialysis
Eligibility:
All Genders
Phase:
NA
Brief Summary
In patients with non-dialysis-dependent end stage kidney disease (ESKD) the common transition of care to renal replacement therapy is dialysis. Each year over 70 000 Chinese transition from non-dialys...
Eligibility Criteria
Inclusion
- Patients who have been diagnosed with end stage kidney disease (eGFR\<15ml/min/1.73m2) or newly started dialysis with 3 months at all hospitals in Yangzhou, China since January 1, 2016
Exclusion
- Patients who have had a history of dialysis and have been transferred to Yangzhou during this period;
- patients who are transferred to a dialysis area outside Yangzhou City
- Patients who give up dialysis treatment
- patient whose renal function recover and stop dialysis treatment;
- Patient who receive kidney transplantation
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT04088526
Start Date
January 1 2016
End Date
December 31 2021
Last Update
September 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology, Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China, 200003